Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are anti-diabetic drugs which improve blood glucose control by blocking reabsorption of glucose from the proximal tubule of kidney. Anti-atherosclerotic properties and cardiovascular protective effects of SGLT2i have been demonstrated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakoshima, Mariko, Yanai, Hidekatsu, Kakuta, Kouki, Adachi, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916538/
https://www.ncbi.nlm.nih.gov/pubmed/29707091
http://dx.doi.org/10.14740/jocmr3392w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916538/
https://www.ncbi.nlm.nih.gov/pubmed/29707091
http://dx.doi.org/10.14740/jocmr3392w

Ejemplares similares